Press releases

Guard Therapeutics (publ) today announced its participation as a partner in a newly funded European research consortium under the 2025 Joint Transnational Call from the European Rare Diseases Research Alliance (ERDERA), aimed at accelerating the development of therapies for rare kidney diseases.

Guard Therapeutics (publ) (“Guard” or the “Company”) announces today that Redeye Aktiebolag (“Redeye”) has been appointed as financial advisor in connection with the strategic review announced by the Company in its press release dated 4 December 2025. The review includes an assessment of potential strategic alternatives, including...

Guard Therapeutics (public) (“Guard” or “the Company”) today provides an assessment of the full results from the Phase 2b POINTER study evaluating RMC-035 in patients undergoing open-heart surgery. As previously communicated, the study did not meet its primary or key secondary efficacy endpoints, although promising signals were observed...

Guard Therapeutics (publ) today announced that top-line results from the company’s Phase 2b POINTER study with the investigational drug candidate RMC-035 have been selected for oral presentation on November 6 as a Late-Breaking Clinical Trial at the scientific conference American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX...

Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery (last patient last visit). The study is evaluating the company’s drug candidate, RMC-035, as a kidney-protective treatment for patients undergoing...